Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

CompletedOBSERVATIONAL

Enrollment

141

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

June 7, 2019

Study Completion Date

June 7, 2019

Conditions

Diabetic Macular Edema

Interventions

DRUG

Dexamethasone intravitreal implant

Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.

Trial Locations (1)

Clinical Trials Registry Team, Irvine